Funder: Alnylam Pharmaceuticals
Due Dates: Rolling (monthly review; submit ≥45 days before activity start)
Funding Amounts: No set minimum or maximum; awards may be less than requested; varies by project
Summary: Supports independent educational activities (CME, non-CME, and RFP responses) advancing clinical knowledge and patient care in ATTR amyloidosis, AHP, and PH1.
Key Information: Only organizations (not individuals) are eligible; requests must be in English and submitted via portal.